Paediatric empyema in New Zealand: a tale of two cities
Cameron Burton, Tony Walls, Neil Price
1Senior Lecturer, Department of Paediatrics, University of Auckland Paediatric Infectious Diseases Consultant, Starship Children's Health, ADHB Postal Address: Level 5 offices, Starship Children's Health, ADHB, Park Road, Grafton, Auckland, New Zealand. e.best@auckland.ac.nz.
Aims:
We aimed to identify the causative organisms and sensitivities in community-acquired paediatric empyema at Starship Children's Hospital and Christchurch Hospital and to determine if current antibiotic recommendations are appropriate.
Methods:
Retrospective analysis was undertaken of all cases with clinical, radiological, and microbiological evidence of empyema at Starship Children's Hospital and Christchurch Hospital between June 2009 and March 2013 (3.8 years), and January 2009 and May 2014 (5.4 years) respectively.
Results:
Ninety-eight children were managed with empyema at Starship Children's Hospital and 30 children at Christchurch Hospital. Staphylococcus aureus was the most common pathogen identified at both sites followed by Streptococcus pneumoniae. A significant proportion had no pathogen identified. Amongst S.aureus isolates, 1/5th were methicillin-resistant, contributing 8% of all culture positive empyema cases. Māori and Pacific groups were over-represented. Cases occurred more often in boys and those <5 years. Blood cultures and S.pneumoniae pleural antigen were important in diagnosis.
Conclusions:
Our audit confirms the important role of S.aureus in paediatric empyema in New Zealand and a high rate of this disease, particularly in the North Island. Antimicrobial susceptibilities of the pathogens of empyema demonstrate current initial antibiotic recommendation.
More Related Videos
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pneumonia III: Complications and Assessment
Atypical Pneumonia
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:


